Share the post "Nectar Lifesciences Limited Shareholding Update: An Examination of Financial Performance for FY (Q4-Mar 2023-2024)"
Shareholder Name | Previous Quater Quantity(In Crores) | Current Quater Quantity(In Crores) | Previous Quater Shares(in %) | Current Quater Shares(in %) | Quater to Quater Difference |
---|---|---|---|---|---|
Promoters | 9.95 | 9.95 | 55.8 | 55.8 | 0 |
Public | 5.00 | 4.85 | 28.06 | 27.21 | -0.85 % |
DII | 0 | 0 | 0 | 0 | 0 |
FII | 2.87 | 3.03 | 16.11 | 16.97 | +0.86 % |
Government | 0.00 | 0.00 | 0.02 | 0.02 | 0 |
Let’s delve deeper into the statistics of the investors, which could have contributed to the fluctuations in the shareholding pattern.
Shareholder Name | Previous Quarter Quantity (In Crores) | Current Quarter Quantity (In Crores) | Previous Quater Shares (in %) | Current Quater Shares (in %) | Quater-to-Quater Difference (%) |
---|---|---|---|---|---|
Resident Individuals holding nominal share capital up to Rs. 2 lakhs | 4.215 | 3.778 | 23.64 | 21.19 | -2.45 % |
Resident Individuals holding nominal share capital in excess of Rs. 2 lakhs | 0.124 | 0.380 | 0.7 | 2.13 | + 1.43 % |
Non Resident Indians (NRIs) | 0.098 | 0.084 | 0.55 | 0.47 | -0.08 % |
Bodies Corporate | 0.316 | 0.283 | 1.77 | 1.59 | -0.18 % |
Any Other (specify) | 0.240 | 0.315 | 1.34 | 1.77 | + 0.43 % |
HUF | 0.240 | 0.315 | 1.34 | 1.76 | + 0.42 % |
Shareholder Name | Previous Quarter Quantity (In Crores) | Current Quarter Quantity (In Crores) | Previous Quater Shares (in %) | Current Quater Shares (in %) | Quater-to-Quater Difference (%) |
---|---|---|---|---|---|
Foreign Portfolio Investors Category I | 0.034 | 0.176 | 0.19 | 0.99 | + 0.8 % |
Foreign Portfolio Investors Category II | 0.239 | 0.249 | 1.34 | 1.4 | + 0.06 % |
28
3-Year Profit
-37
5-Year Profit
-23
10-Year Profit
41.9
Current Price
941
Market Cap
Upon examining the financial data for BSE code 532649, it becomes clear that the company achieved a notable five-year profit of -37 percents, which impressively increased to 28 percents in the three-year window. This upward trajectory, however, has been overshadowed by the latest trailing twelve-month (TTM) figures, which indicate a concerning loss of 125 percents. This financial loss is further compounded by the fact that the company has not recorded any sales across any of the timeframes under consideration. Such an unusual situation might suggest that the company operates under an unconventional business model, which could potentially carry higher risks. In terms of stock performance, the company’s stock price has seen a decline, falling from 28 percents over the five-year period to just 74 percents in the last year. The ten-year average stock price, which sits at 1 percents, highlights long-term volatility, casting doubt on the company's ability to sustain its market position over time. This warrants further investigation into the factors driving these fluctuations.
The company has a market capitalization of ₹941 crore and is currently trading at ₹41.9 per share. Historically, the stock has fluctuated within a range of ₹56.5 / 21.2, reflecting both the opportunities and risks that investors perceive in the company. The P/E ratio, at 153, is relatively high, suggesting that the market has priced in substantial future growth or is willing to pay a premium for the company’s current earnings. The book value per share stands at ₹47.7, which reflects the net asset value of the company divided by the number of outstanding shares. The dividend yield is 0.00%, providing shareholders with a consistent return on their investment. ROCE is 5.97%, indicating how well the company is using its capital to generate profits, while ROE at 0.46% highlights the returns generated from shareholders' equity. The debt-to-equity ratio is 0.59, signaling low financial leverage, which is typically seen as a positive indicator of financial health. However, the company’s negative net cash flow of ₹2.23 crore might raise concerns about its cash generation capabilities or capital expenditures. With a Piotroski score of 8.00, the company's financial stability is evaluated on several factors. Finally, the Graham Number, at ₹17.2, provides an estimate of the stock’s intrinsic value, while the Price-to-Book (P/B) ratio of 0.88 highlights that the stock is trading at a premium to its book value, potentially reflecting positive market sentiment or overvaluation risks.